Two Sigma Advisers LP Raises Stock Position in Certara, Inc. (NASDAQ:CERT)

Two Sigma Advisers LP grew its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 35.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,500 shares of the company's stock after purchasing an additional 23,000 shares during the period. Two Sigma Advisers LP owned approximately 0.05% of Certara worth $932,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in CERT. Principal Financial Group Inc. raised its holdings in shares of Certara by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock valued at $5,660,000 after buying an additional 15,739 shares during the period. First Trust Advisors LP acquired a new position in Certara in the 4th quarter valued at about $140,000. Vontobel Holding Ltd. purchased a new stake in Certara during the fourth quarter worth about $1,295,000. Raymond James Financial Inc. acquired a new position in shares of Certara in the fourth quarter valued at approximately $3,628,000. Finally, Proficio Capital Partners LLC purchased a new stake in Certara during the 4th quarter worth approximately $148,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CERT shares. TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price target for the company. Stephens reissued an "overweight" rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. William Blair restated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Robert W. Baird lifted their price objective on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Finally, KeyCorp boosted their price objective on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $15.67.

Certara Stock Up 4.2%

Shares of CERT stock traded up $0.46 on Tuesday, reaching $11.46. 1,582,263 shares of the stock were exchanged, compared to its average volume of 1,344,071. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of -57.30, a PEG ratio of 9.29 and a beta of 1.57. The business's 50 day moving average price is $11.88 and its 200 day moving average price is $11.81. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $17.76.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. As a group, sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.